The medical community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s exhibiting significant promise in clinical trials for managing obesity. Unlike some available weight loss treatments, retatrutide appears to deliver a greater substantial decrease in body mass and enhance metabolic function, parti